Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2017

View Archived Issues

Boehringer Ingelheim and MiNa Therapeutics to collaborate on compounds for fibrotic liver diseases

CellSight, Boehringer Ingelheim to evaluate use of VisAcT in monitoring immune-oncological therapies

AVERTS-2 phase III trial of Otividex meets primary efficacy endpoint

ImmunoMolecular Therapeutics as new spinout of Barbara Davis Center for Diabetes

FDA grants QIDP status to BIOC-51

Protagonist Therapeutics begins phase I study of PTG-200

FDA accepts Otsuka's resubmitted NDA for tolvaptan

Phase I study of BRAF inhibitor PLX-8394 identifies dose for phase II

FDA approves Adcetris in new indication

NICE recommends Mavenclad in final appraisal determination

Sage's phase III trials of brexanolone in postpartum depression meet primary endpoints

Principia to grant Sanofi worldwide license to develop and commercialize PRN-2246

Inotrem collaborates with Roche Diagnostics on septic shock companion diagnostic

FDA approves Heplisav-B for prevention of hepatitis B in adults

FDA approves Cinvanti for prevention of acute and delayed chemotherapy-induced nausea and vomiting

Lundbeck reports highlights of third quarter 2017

Alnylam reaches alignment with FDA on safety measures for fitusiran program

vTv Therapeutics initiates simplici-T1 study of TTP-399 in type 1 diabetes

New phase I trial studies polio vaccine JNJ-64152348 in healthy adults

Zosano initiates long-term safety study of M-207 for migraine

Merck KGaA describes novel PDH kinase 2 inhibitors

Duke University discovers bacterial LpxC inhibitors

Novel retinoid RORgammaT receptor modulators identified at Janssen

Yuhan patents new PI3Kdelta inhibitors

Guangzhou Henovcom Bioscience discloses novel influenza virus neuraminidase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.